AAPL342.37-1.80 (-0.52%) ▼|ABBV291.31+3.07 (+1.07%) ▲|ABT109.93-3.67 (-3.23%) ▼|ACN260.50-4.66 (-1.76%) ▼|ADBE239.30-7.14 (-2.90%) ▼|AMAT332.72+13.47 (+4.22%) ▲|AMD449.04+44.64 (+11.04%) ▲|AMGN460.42+0.14 (+0.03%) ▲|AMT188.79-5.20 (-2.68%) ▼|AMZN259.30-0.91 (-0.35%) ▼|AVGO293.69+2.16 (+0.74%) ▲|AXP320.99-3.98 (-1.22%) ▼|BA173.40+0.90 (+0.52%) ▲|BAC49.42-0.34 (-0.68%) ▼|BKNG160.67-8.06 (-4.77%) ▼|BLK1,178.87+8.20 (+0.70%) ▲|BMY62.14-0.99 (-1.57%) ▼|BNY147.72+0.23 (+0.16%) ▲|BRK-B570.89-1.44 (-0.25%) ▼|C119.05+0.60 (+0.51%) ▲|CAT558.63+4.99 (+0.90%) ▲|CL96.56-2.13 (-2.16%) ▼|CMCSA24.39-0.56 (-2.24%) ▼|COF201.87-1.97 (-0.97%) ▼|COP136.27+0.81 (+0.60%) ▲|COST1,053.56-12.03 (-1.13%) ▼|CRM213.65-8.76 (-3.94%) ▼|CSCO93.85-1.87 (-1.95%) ▼|CVS83.85+2.52 (+3.10%) ▲|CVX212.61-0.32 (-0.15%) ▼|DE671.65+8.34 (+1.26%) ▲|DHR230.25+3.91 (+1.73%) ▲|DIS116.75-0.47 (-0.40%) ▼|DUK127.78-2.30 (-1.77%) ▼|EMR162.35-0.26 (-0.16%) ▼|FDX308.14-8.66 (-2.73%) ▼|GD354.06-2.29 (-0.64%) ▼|GE323.24+8.51 (+2.70%) ▲|GEV774.11+3.60 (+0.47%) ▲|GILD166.89-0.68 (-0.41%) ▼|GM86.16-3.17 (-3.55%) ▼|GOOG283.93+2.19 (+0.78%) ▲|GOOGL284.78+2.21 (+0.78%) ▲|GS865.82-3.13 (-0.36%) ▼|HD343.47-6.47 (-1.85%) ▼|HON220.05+4.27 (+1.98%) ▲|IBM245.00-2.11 (-0.85%) ▼|INTC56.28+4.03 (+7.71%) ▲|INTU341.50-13.34 (-3.76%) ▼|ISRG452.80-15.72 (-3.36%) ▼|JNJ276.22+3.90 (+1.43%) ▲|JPM334.49-2.85 (-0.84%) ▼|KO95.67-0.06 (-0.06%) ▼|LIN515.25-5.98 (-1.15%) ▼|LLY1,354.00-10.73 (-0.79%) ▼|LMT567.08-9.08 (-1.58%) ▼|LOW224.55-2.69 (-1.18%) ▼|LRCX200.44+15.24 (+8.23%) ▲|MA652.70-3.22 (-0.49%) ▼|MCD276.52-1.52 (-0.55%) ▼|MDLZ66.02-0.80 (-1.20%) ▼|MDT101.80-3.04 (-2.90%) ▼|META610.15+5.07 (+0.84%) ▲|MMM185.15-2.62 (-1.40%) ▼|MO76.12-1.46 (-1.88%) ▼|MRK146.73-0.21 (-0.14%) ▼|MS181.44-1.00 (-0.55%) ▼|MSFT530.61-5.32 (-0.99%) ▼|MU690.00+33.61 (+5.12%) ▲|NEE86.95-1.30 (-1.47%) ▼|NFLX63.41-2.15 (-3.28%) ▼|NKE38.59-0.97 (-2.45%) ▼|NOW101.97-0.39 (-0.38%) ▼|NVDA186.64+5.04 (+2.78%) ▲|ORCL116.10+0.94 (+0.82%) ▲|PEP141.34-1.37 (-0.96%) ▼|PFE29.39-0.06 (-0.20%) ▼|PG165.40-1.70 (-1.02%) ▼|PLTR160.38+5.39 (+3.48%) ▲|PM197.88-3.62 (-1.80%) ▼|QCOM165.41+8.66 (+5.52%) ▲|RTX189.53-2.35 (-1.22%) ▼|SBUX105.41-0.75 (-0.71%) ▼|SCHW91.49-1.09 (-1.18%) ▼|SO92.34-1.00 (-1.07%) ▼|SPG228.42+1.87 (+0.83%) ▲|T21.63-0.19 (-0.87%) ▼|TMO694.76+17.82 (+2.63%) ▲|TMUS162.01+1.42 (+0.88%) ▲|TSLA358.22+14.53 (+4.23%) ▲|TXN277.36-0.79 (-0.28%) ▼|UBER68.59-0.19 (-0.28%) ▼|UNH394.15-1.57 (-0.40%) ▼|UNP290.16-7.79 (-2.61%) ▼|UPS108.30-2.74 (-2.47%) ▼|USB59.45-0.30 (-0.50%) ▼|V422.65+0.06 (+0.01%) ▲|VZ45.69-0.43 (-0.93%) ▼|WFC83.94-0.36 (-0.43%) ▼|WMT125.52-2.20 (-1.72%) ▼|XOM165.87+0.57 (+0.34%) ▲|AAPL342.37-1.80 (-0.52%) ▼|ABBV291.31+3.07 (+1.07%) ▲|ABT109.93-3.67 (-3.23%) ▼|ACN260.50-4.66 (-1.76%) ▼|ADBE239.30-7.14 (-2.90%) ▼|AMAT332.72+13.47 (+4.22%) ▲|AMD449.04+44.64 (+11.04%) ▲|AMGN460.42+0.14 (+0.03%) ▲|AMT188.79-5.20 (-2.68%) ▼|AMZN259.30-0.91 (-0.35%) ▼|AVGO293.69+2.16 (+0.74%) ▲|AXP320.99-3.98 (-1.22%) ▼|BA173.40+0.90 (+0.52%) ▲|BAC49.42-0.34 (-0.68%) ▼|BKNG160.67-8.06 (-4.77%) ▼|BLK1,178.87+8.20 (+0.70%) ▲|BMY62.14-0.99 (-1.57%) ▼|BNY147.72+0.23 (+0.16%) ▲|BRK-B570.89-1.44 (-0.25%) ▼|C119.05+0.60 (+0.51%) ▲|CAT558.63+4.99 (+0.90%) ▲|CL96.56-2.13 (-2.16%) ▼|CMCSA24.39-0.56 (-2.24%) ▼|COF201.87-1.97 (-0.97%) ▼|COP136.27+0.81 (+0.60%) ▲|COST1,053.56-12.03 (-1.13%) ▼|CRM213.65-8.76 (-3.94%) ▼|CSCO93.85-1.87 (-1.95%) ▼|CVS83.85+2.52 (+3.10%) ▲|CVX212.61-0.32 (-0.15%) ▼|DE671.65+8.34 (+1.26%) ▲|DHR230.25+3.91 (+1.73%) ▲|DIS116.75-0.47 (-0.40%) ▼|DUK127.78-2.30 (-1.77%) ▼|EMR162.35-0.26 (-0.16%) ▼|FDX308.14-8.66 (-2.73%) ▼|GD354.06-2.29 (-0.64%) ▼|GE323.24+8.51 (+2.70%) ▲|GEV774.11+3.60 (+0.47%) ▲|GILD166.89-0.68 (-0.41%) ▼|GM86.16-3.17 (-3.55%) ▼|GOOG283.93+2.19 (+0.78%) ▲|GOOGL284.78+2.21 (+0.78%) ▲|GS865.82-3.13 (-0.36%) ▼|HD343.47-6.47 (-1.85%) ▼|HON220.05+4.27 (+1.98%) ▲|IBM245.00-2.11 (-0.85%) ▼|INTC56.28+4.03 (+7.71%) ▲|INTU341.50-13.34 (-3.76%) ▼|ISRG452.80-15.72 (-3.36%) ▼|JNJ276.22+3.90 (+1.43%) ▲|JPM334.49-2.85 (-0.84%) ▼|KO95.67-0.06 (-0.06%) ▼|LIN515.25-5.98 (-1.15%) ▼|LLY1,354.00-10.73 (-0.79%) ▼|LMT567.08-9.08 (-1.58%) ▼|LOW224.55-2.69 (-1.18%) ▼|LRCX200.44+15.24 (+8.23%) ▲|MA652.70-3.22 (-0.49%) ▼|MCD276.52-1.52 (-0.55%) ▼|MDLZ66.02-0.80 (-1.20%) ▼|MDT101.80-3.04 (-2.90%) ▼|META610.15+5.07 (+0.84%) ▲|MMM185.15-2.62 (-1.40%) ▼|MO76.12-1.46 (-1.88%) ▼|MRK146.73-0.21 (-0.14%) ▼|MS181.44-1.00 (-0.55%) ▼|MSFT530.61-5.32 (-0.99%) ▼|MU690.00+33.61 (+5.12%) ▲|NEE86.95-1.30 (-1.47%) ▼|NFLX63.41-2.15 (-3.28%) ▼|NKE38.59-0.97 (-2.45%) ▼|NOW101.97-0.39 (-0.38%) ▼|NVDA186.64+5.04 (+2.78%) ▲|ORCL116.10+0.94 (+0.82%) ▲|PEP141.34-1.37 (-0.96%) ▼|PFE29.39-0.06 (-0.20%) ▼|PG165.40-1.70 (-1.02%) ▼|PLTR160.38+5.39 (+3.48%) ▲|PM197.88-3.62 (-1.80%) ▼|QCOM165.41+8.66 (+5.52%) ▲|RTX189.53-2.35 (-1.22%) ▼|SBUX105.41-0.75 (-0.71%) ▼|SCHW91.49-1.09 (-1.18%) ▼|SO92.34-1.00 (-1.07%) ▼|SPG228.42+1.87 (+0.83%) ▲|T21.63-0.19 (-0.87%) ▼|TMO694.76+17.82 (+2.63%) ▲|TMUS162.01+1.42 (+0.88%) ▲|TSLA358.22+14.53 (+4.23%) ▲|TXN277.36-0.79 (-0.28%) ▼|UBER68.59-0.19 (-0.28%) ▼|UNH394.15-1.57 (-0.40%) ▼|UNP290.16-7.79 (-2.61%) ▼|UPS108.30-2.74 (-2.47%) ▼|USB59.45-0.30 (-0.50%) ▼|V422.65+0.06 (+0.01%) ▲|VZ45.69-0.43 (-0.93%) ▼|WFC83.94-0.36 (-0.43%) ▼|WMT125.52-2.20 (-1.72%) ▼|XOM165.87+0.57 (+0.34%) ▲|
11.3 C
New York
Monday, November 9, 2026

Tag: form

newsFORsourcecompanycontentinformationreleases1market

LAMB WESTON ALERT: Bragar Eagel & Squire, P.C. is Investigating Lamb Weston Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact...

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Lamb Weston Holdings, Inc. (NYSE: LW) on behalf of long-term stockholders following a class action complaint that was filed against Lamb Weston on June 13, 2024 with a Class Period from July 25, 2023, through April 3, 2024. Our investigation concerns whether the board of directors of Lamb Weston have breached their fiduciary duties to the company.

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA’s 85th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...

AUGMENTED WORLD EXPO REVEALS 2025 AUGGIE AWARD WINNERS, BEST IN SHOW AND XR LEGENDS

AWE Celebrates Innovation and Legacy in an Unforgettable Milestone for the XR Industry LONG BEACH, Calif., June 12, 2025 /PRNewswire/ -- Augmented World Expo USA...

BEST SPAC I Acquisition Corp. Announces Pricing of $55 Million Initial Public Offering

HONG KONG, June 12, 2025 /PRNewswire/ -- BEST SPAC I Acquisition Corp. (the "Company"), a blank check company incorporated as a British Virgin Islands business...

CIVI Lead Plaintiff Deadline Approaching – CIVI Stockholders Should Contact Robbins LLP for Information About Leading the Civitas Resources, Inc. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Civitas Resources, Inc. (CIVI) Misled Investors Regarding the Company's Production Capabilities

PEPG Investor Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against PepGen Inc.

SAN DIEGO, June 12, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise...

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis...

VSTS Investor Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vestis Corporation

Robbins LLP is Investigating Allegations that Vestis Corporation (VSTS) Misled Investors regarding Customer Growth

Republic of Peru Announces Results of Exchange and Tender Offers

LIMA, Peru, June 12, 2025 /PRNewswire/ -- The Republic of Peru ("Peru"), in accordance with its previously-announced offers to (i) exchange certain of Peru's outstanding...

Hapbee Is Upgrading U.S. Listing to OTCID to Expand Investor Access and Increase Market Visibility

Hapbee Also Updates Status of Audited Financial Statements 
Hapbee Also Updates Status of Audited Financial Statements

Atrium Mortgage Investment Corporation Announces $30 Million Public Offering of Convertible Unsecured Subordinated Debentures

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

TAMMY BARLET, STUDENT VETERANS OF AMERICA VP OF GOVERNMENT AFFAIRS, NAMED 2025 BUSH INSTITUTE STAND-TO VETERAN LEADERSHIP PROGRAM SCHOLAR

Brings the Student Veterans of America's veteran advocacy mission to leadership development program WASHINGTON, June 12, 2025 /PRNewswire/ -- Tammy Barlet, Vice President of Government Affairs at Student Veterans of America (SVA) has been...

DBV Technologies to Participate in Upcoming EAACI Congress 2025

Châtillon, France, June 12, 2025

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsForm

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers